This study examined changes and inequities in Indonesia’s diabetes care cascade over a ten-year period (2013–2023). The authors sought to quantify trends in diabetes prevalence, diagnosis, treatment, and glycemic control; to identify sociodemographic predictors of progression through the cascade; and to assess progress toward the global targets of 80% diagnosis and 80% glycemic control among those diagnosed.
The analysis used nationally representative health survey data collected at three time points and framed outcomes across the standard cascade steps: diagnosis, treatment, and control.
The investigators analyzed publicly available, nationally representative survey datasets collected by the Ministry of Health of the Republic of Indonesia: Riskesdas (Riset Kesehatan Dasar) 2013 and 2018, and the Survei Kesehatan Indonesia (SKI) 2023. The surveys provided population-weighted data suitable for national estimates.
Diabetes status in the surveys was defined using fasting plasma glucose and oral glucose tolerance tests, consistent with the source datasets. The authors estimated rates for diagnosis, treatment, and control at each survey year. They used survey-weighted logistic regression models to examine associations between sociodemographic factors and progression through the cascade.
Ethical clearance for the original surveys came from the National Health Research Ethics Committee of the Ministry of Health. Because the current work was a secondary analysis of anonymized, public data, it was exempt from additional institutional review oversight. The authors also note that the manuscript is a preprint and has not undergone peer review.
The cascade steps reported in the study are defined as follows based on the source datasets and analyses: presence of diabetes (biochemical definition using fasting plasma glucose and OGTT), documented or self-reported diagnosis among those meeting biochemical criteria, receipt of any treatment among those diagnosed, and achievement of glycemic control among those treated or diagnosed (as reported by the authors). The exact thresholds used for control were those applied in the underlying surveys but are not expanded on beyond the summary provided in the source abstract.
Prevalence of diabetes among adults aged 15 years and older remained largely stable across the three surveys, ranging from 10.7% to 11.8% between 2013 and 2023.
Across the decade there were measurable improvements in cascade indicators:
Diagnosis: increased from 15.1% (95% CI 13.4–16.7) in 2013 to 20.7% (95% CI 18.5–22.9) in 2023.
Treatment: nearly doubled from 10.5% (95% CI 9.1–11.9) in 2013 to 19.0% (95% CI 16.9–21.2) in 2023.
Glycemic control: rose modestly from 4.6% (95% CI 3.6–5.6) in 2013 to 6.5% (95% CI 5.2–7.8) in 2023.
Despite these gains, the absolute levels remained low. The authors report that Indonesia is far below the global 80/80 targets: in 2023 nearly four in five people with diabetes were undiagnosed and control among cases was below 10%.
Survey-weighted logistic regression identified several sociodemographic factors associated with greater likelihood of moving through the cascade (diagnosis → treatment → control). Specifically, older age, urban residence, higher socioeconomic status, and health insurance coverage were associated with higher odds of being diagnosed, receiving treatment, and achieving control. The abstract summarizes these relationships but does not provide a full list of covariates or model specifications beyond those cited associations and adjusted odds ratios for wealth quintiles.
A central finding was persistent wealth-related inequality in the diabetes care cascade. In 2023, diagnosed cases were disproportionately concentrated in the wealthier strata: the richest quintile accounted for 35.3% (95% CI 29.0–41.7) of diagnosed cases while the poorest quintile accounted for only 11.0% (95% CI 7.9–14.2).
Comparing the highest to the lowest wealth quintiles, the authors report adjusted odds ratios of:
These estimates indicate substantially higher likelihoods of diagnosis and treatment among wealthier groups, with a more modest but still significant advantage for control.
The authors emphasize that these inequalities persisted despite near-universal insurance coverage expansions, suggesting that coverage alone had not translated into equitable diabetes detection and management across socioeconomic groups.
Between 2013 and 2023 Indonesia made measurable progress in the diabetes care cascade, with increases in diagnosis and treatment and a small rise in glycemic control. However, the absolute levels of detection and control remain far below the global 80% diagnosis and 80% control goals. Nearly 80% of diabetes cases remained undiagnosed in 2023, and control rates stayed under 10%.
Persistent wealth-based disparities indicate that improvements have not been evenly distributed. The authors conclude that equity-focused strategies are needed, including targeted screening for underserved groups and strengthening of primary care services to translate insurance coverage into effective and equitable care.
The analysis used publicly available data from the Ministry of Health data repositories (Riskesdas 2013 and 2018; SKI 2023). Ethical clearance for the original surveys was obtained from the National Health Research Ethics Committee of the Ministry of Health. The current analysis was exempt from further IRB oversight because it used anonymized, non-identifiable secondary data. The manuscript is a preprint posted on medRxiv and has not been peer reviewed; the authors note this status in the source document.
Note: the abstract provides point estimates, confidence intervals, and adjusted odds ratios cited above. Additional methodological details, full model specifications, and subgroup analyses—if present—are not reported in the abstract and are available in the full preprint and underlying datasets referenced by the authors.